Clinical And Therapeutic Studies Of Human Filariasis

为了更好地了解丝虫病(丝虫病、血吸虫病、淋巴丝虫病)的发病机制，对这些和其他相关非丝虫病(线虫病、疟疾)患者的临床评估进行了详细研究。此外，还详细介绍了治疗后的炎症反应及其诱导的潜在机制。特别是，控制嗜酸性粒细胞的诱导和细胞向治疗后炎症部位的运输已经被研究过。沃尔巴克氏菌内共生菌作为治疗靶标和炎症诱导剂的重要性也已详细介绍。 在2003财年，我们证明了在马里，伊维菌素/阿苯达唑治疗淋巴丝虫病后出现的不良反应相对较少，并表明合并感染永久曼索氏菌对改变治疗后的反应几乎没有作用。

To understand better the pathogenesis of filarial infections (onchocerciasis, loiaisis, lymphatic filarasis) clinical assessments of patients with these and other related non-filarial (strongyloides, malaria) infections have been studied in detail. Moreover, the post-treatment inflammatory responses and the underlying mechanisms in their induction have been detailed. In particular, the control of eosinophil induction and cell trafficking to sites of post-treatment inflammation has been studied. The importance of the Wolbachia endosymbiont both as a therapeutic target and as a inducer of inflammation has been detailed as well. In FY 2003, we demonstrated the relative paucity of adverse reactions seen following ivermectin/albendazole treatment of lymphatic filariasis in Mali and have shown that co-infection with Mansonella perstans does little to alter the post-treatment reactions.